Lundbeck, a global biopharmaceutical organization dedicated exclusively to brain health advancement, has announced an expanded strategic partnership with EVERSANA, a leading independent provider of commercial services to the life sciences industry. This collaboration marks a significant broadening of their existing relationship, with both organizations committing to advance AI-powered commercialization across Lundbeck’s entire U.S. commercial organization.
Scaling AI-Powered Commercialization Across Operations
The partnership centers on expanding the deployment of EVERSANA’s AI Agency platform alongside complementary commercialization capabilities. This expansion will create a scalable framework designed to accelerate strategy development, content creation, omnichannel engagement and commercial execution across multiple functional areas.
The collaboration will enable Lundbeck to scale AI-powered commercialization capabilities across marketing, medical communications, market access and media operations. The companies will additionally explore new use cases specifically designed to enhance operational performance and strengthen commercial excellence throughout the organization.
Supporting the Focused Innovator Strategy
This expanded partnership directly supports Lundbeck’s Focused Innovator strategy and the organization’s broader ambition to build bionic capabilities—an approach that combines human expertise with artificial intelligence to achieve results neither can deliver independently.
Tom Gibbs, Executive Vice President and President of Lundbeck U.S., said, “Our ambition is to bring human expertise and artificial intelligence together to strengthen how we think, decide and execute across our business. Building on the progress we have made with EVERSANA, our expanded collaboration will help us scale bionic capabilities responsibly across our commercial organization, improve the speed and quality of execution and ultimately, help us deliver greater value to our customers and patients while maintaining the high standards that define our business.”
Responsible AI Deployment and Compliance Focus
Both organizations share a commitment to deploying artificial intelligence responsibly and at scale while maintaining the compliance, quality, scientific rigor and governance standards required for the life sciences industry. This approach ensures that healthcare providers, patients, families and communities receive support grounded in the industry’s most rigorous standards.
The partnership follows successful initial deployment of EVERSANA’s AI-powered capabilities supporting Lundbeck’s commercialization activities. During this pilot phase, both organizations introduced AI-driven workflows to accelerate strategic planning, content development and commercial execution while maintaining rigorous medical, legal and regulatory review processes.
The AI Agency Platform and Operating Model
EVERSANA’s AI Agency, launched in 2025, represents an end-to-end AI-powered commercialization platform specifically built for the life sciences sector. Developed in collaboration with Google Cloud, this platform combines agentic AI, advanced automation and human expertise to accelerate strategy, content and omnichannel engagement development while supporting compliance and governance requirements unique to pharmaceutical operations.
Faruk Capan, Chief Innovation Officer at EVERSANA, said, “What makes this partnership unique is that we’re not simply introducing AI tools into existing workflows. Together, we’re implementing an AI-powered operating model designed specifically for life sciences. By combining agentic AI, embedded compliance and human expertise, we can help commercial teams accelerate execution while maintaining the quality and scientific rigor the industry demands.”
The Future of Pharmaceutical Commercialization
Mark Thierer, Chief Executive Officer of EVERSANA, said, “The future of commercialization will belong to organizations that successfully combine human expertise with AI-driven execution. Lundbeck is advancing innovation and actively implementing new ways of working. Together, we are creating a model that pairs the power of artificial intelligence with deep life sciences expertise to help commercial teams move faster, operate more efficiently and deliver greater impact.”
